Wheeler Bio Partners with MindImmune Therapeutics
Wheeler Bio, a prominent U.S.-based contract development and biomanufacturing organization (CDMO), has recently concluded a significant partnership agreement with MindImmune Therapeutics. This collaboration marks a pivotal moment in the fight against Alzheimer's disease, focusing on MindImmune's lead program, known as MITI-101. Under this agreement, Wheeler Bio will leverage its innovative ModularCMC™ platform, which is tailored for specialized antibody-based processes to advance MITI-101.
Understanding MITI-101
MITI-101 represents an ambitious effort to disrupt the progression of Alzheimer’s disease. It is engineered to block the entry of CD11c+ immune cells into the brain, which are implicated in the neuroinflammatory processes that contribute to Alzheimer’s. This unique monoclonal antibody approach seeks to tackle the recruitment of harmful peripheral immune cells, a significant factor contributing to neurodegenerative diseases.
The Role of Wheeler Bio's ModularCMC™ Platform
Wheeler Bio is dedicated to expediting the journey from discovery to clinical studies. Their ModularCMC™ platform stands out as a powerful tool in the biopharmaceutical sector, known for its agility and capability to scale efficiently. This platform not only enhances the manufacturing process but also ensures that the collaboration with MindImmune remains focused on delivering results swiftly and effectively. The company's extensive expertise complements this partnership, as Wheeler Bio's team has a history of success with over 1,400 unique molecules.
Thoughts from Leadership
Patrick Lucy, the President and CEO of Wheeler Bio, expressed enthusiasm about this partnership, highlighting its impact on addressing a significant unmet medical need in the field of Alzheimer's treatment. He noted, "We are thrilled to establish this partnership with MindImmune to advance this promising therapeutic focused on a disease where there is significant unmet medical need. MindImmune's previous collaborations have paved the way for this moment, and we are excited about the potential they see in our ModularCMC efforts. This partnership symbolizes hope for patients and families affected by Alzheimer’s disease."
Similarly, Stevin Zorn, President and CEO of MindImmune Therapeutics, remarked on the implications of MITI-101, stating that this strategy offers a groundbreaking approach to mitigating the inflammation associated with neurodegenerative disorders. By preventing these harmful cells from infiltrating the brain, MITI-101 emerges as a beacon of hope for many.
About MindImmune Therapeutics
MindImmune Therapeutics is at the forefront of developing novel therapies aimed at combating neuroinflammation linked to neurodegenerative diseases like Alzheimer’s. With its headquarters at the University of Rhode Island, the company is pioneering research in inhibiting the adverse trafficking of immune cells in response to neurological pathology. Their commitment to innovation places them in a crucial position to contribute to transformative breakthroughs in neurodegenerative disease management.
About Wheeler Bio
Wheeler Bio has distinguished itself as a pioneer in contract development and manufacturing. Through its innovative ModularCMC™ platform, the organization focuses on the efficient transition of antibody therapeutics from discovery into clinical phases while maintaining scalability for advanced development. Their High Science/High Touch approach emphasizes meticulous development and cGMP manufacturing, which is crucial for the future of biopharmaceuticals.
Frequently Asked Questions
What is the purpose of the Wheeler Bio and MindImmune partnership?
The partnership aims to advance MindImmune's lead program, MITI-101, targeting Alzheimer's disease through innovative biomanufacturing and process development.
What are the main features of the MITI-101 program?
MITI-101 is designed to block CD11c+ immune cell entry into the brain, preventing their harmful effects and addressing neuroinflammation linked to Alzheimer's.
How does Wheeler Bio support drug development?
Wheeler Bio utilizes its ModularCMC™ platform to streamline the drug development process, focusing on speed, scalability, and transparency throughout.
Who are the executives leading this initiative?
Patrick Lucy is the President and CEO of Wheeler Bio, while Stevin Zorn leads MindImmune Therapeutics, both emphasizing the importance of this collaboration.
What does the future hold for this partnership?
The partnership holds promise for advancements in Alzheimer's treatment, potentially leading to groundbreaking therapies that offer hope to patients and families affected by the disease.
